荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

午间休市 01-15 12:05:00

94.800

+1.650

+1.77%

最高95.950	最低92.750	成交量232.53万
今开94.000	昨收93.150	日振幅3.44%
总市值534.30亿	流通市值197.74亿	总股本5.64亿
成交额2.20亿	换手率1.11%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":94.8,"timestamp":1768449900010,"preClose":93.15,"halted":0,"volume":2325256,"delay":0,"floatShares":208581239,"shares":563608243,"eps":-2.73,"marketStatus":"午间休市","change":1.65,"latestTime":"01-15 12:05:00","open":94,"high":95.95,"low":92.75,"amount":219817168,"amplitude":0.034353,"askPrice":94.85,"askSize":2000,"bidPrice":94.8,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-1.907353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768453200000},"marketStatusCode":3,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":93.15,"openAndCloseTimeList":[[1768440600000,1768449600000],[1768453200000,1768464000000]],"volumeRatio":0.620325,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":107.27,"timestamp":1768447798000,"preClose":103.34,"halted":0,"volume":8180400,"delay":0,"premium":"-21.02"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2603027626","title":"华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2603027626","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603027626?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:11","pubTimestamp":1768439514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华西证券发布研报称，维持荣昌生物“增持”评级，公司自主研发实力强劲，核心产品销售稳定增长，管理团队经验丰富，临床适应症管线稳定推进，海内外布局合理，看好公产品上市后商业化运营能力。根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002926","09995","688331"],"gpt_icon":0},{"id":"2603262688","title":"【券商聚焦】华泰证券：超预期创新药BD带动板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2603262688","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603262688?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:57","pubTimestamp":1768438620,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，步入2026年以来，港股创新药交易不足两周，但已如该机构预期迎来开门红。港股创新药板块流动性大幅修复，且随着JPM医药峰会本周拉开序幕，中国BD交易持续超预期，相比去年同期有较大增长。该机构认为开年以来的流动性修复将带来一波明确的创新药β行情，该机构看好突破前高。外需型CXO在新分子需求的驱动下，业绩持续超预期，有望和创新药实现共振。该机构建议策略上优选中美估值差距较大的创新药资产相应公司；受益于新分子药物（多肽、寡核苷酸及ADC）的涌现，外需型CXO龙头凭借充沛的在手订单+强劲的漏斗效应，整体业绩已进入加速上升通道。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973256","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","BK1610","LU1719994722.HKD","LU0819121731.USD","SG9999004220.SGD","LU2476274308.USD","LU0140636845.USD","LU1688375341.USD","LU1979443071.USD","LU1226288170.HKD","BK1574","BK1588","LU1961090484.USD","06978","LU0516422952.EUR","LU0856984785.SGD","06185","09926","01093","LU0823426480.USD","LU2097828714.EUR","LU1303224171.USD","01877","06160","LU1960683339.HKD","LU0348825331.USD","SG9999002463.SGD","LU0348783233.USD","159992","01801","LU2328871848.SGD","02142","02616","LU1251922891.USD","IE00BZ08YR35.GBP","BK0028","LU1934453819.USD","09995","LU0348827113.USD","LU1993786604.SGD","LU0561508036.HKD","01177","IE00BPRC5H50.USD","09688","601688","LU2488822045.USD","LU1064131003.USD","LU0072913022.USD","BK1515","BK1161"],"gpt_icon":0},{"id":"2603942046","title":"2026开年，创新药迎来暖风","url":"https://stock-news.laohu8.com/highlight/detail?id=2603942046","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603942046?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:39","pubTimestamp":1768383558,"startTime":"0","endTime":"0","summary":"2026年开年以来，创新药板块的情绪明显回暖。进入2026年，这一趋势并未放缓。开年不足半月，整体创新药行业的BD交易高达14起，覆盖小核酸、ADC、双抗、炎症免疫小分子及 AI 制药等多个技术方向。2026年被普遍视为其关键拐点之年，全球医药圈频频传来利好消息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114174511a719ab7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114174511a719ab7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1574","09995","06978","BK1161"],"gpt_icon":1},{"id":"2603644555","title":"每日卖空追踪 | 荣昌生物 01月14日卖空量成交30.4万股，卖空比例为2.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603644555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603644555?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:30","pubTimestamp":1768379443,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间01月14日，跌6.94%，卖空量成交30.4万股，较上一交易日减少85.71%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114164534a7196e8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114164534a7196e8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","LU1969619763.USD","LU2328871848.SGD","BK1583","09995"],"gpt_icon":0},{"id":"2603662033","title":"2026年肿瘤药物研发将驶上 “快车道” ，开年药企合作/并购密集","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662033","media":"制药网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603662033?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:52","pubTimestamp":1768373563,"startTime":"0","endTime":"0","summary":"此次收购，阿斯利康旨在借助Modella AI在人工智能领域的技术优势，进一步强化其在肿瘤药物研发方面的能力。目前，荣昌生物正在中国开展RC148单药及联合疗法治疗多种晚期恶性实体瘤患者的临床研究。2026年，医药企业在肿瘤药物领域的合作与并购的浪潮预计将持续。众多企业将通过技术突破、临床提速、资源整合，推动肿瘤药物研发进入 “快车道”，在此背景下，AI药物、下一代细胞疗法、新型偶联药物等或将有望实现临床与商业化双突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114145643a4c2036c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114145643a4c2036c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09995","LU1969619763.USD","BK1161","AZN","BK1583","03696","LU2328871848.SGD"],"gpt_icon":1},{"id":"1163497020","title":"异动解读 | 荣昌生物盘中大跌5.94%，与艾伯维56亿美元授权协议后现获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1163497020","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163497020?lang=zh_cn&edition=full","pubTime":"2026-01-14 13:04","pubTimestamp":1768367069,"startTime":"0","endTime":"0","summary":"荣昌生物(09995)今日盘中大幅下跌5.94%，引起市场关注。消息面上，该公司近日与跨国药企艾伯维签署了关于双特异性抗体RC148的独家授权协议，潜在交易总额高达56亿美元。这一重大利好消息此前可能已推动股价上涨，今日的下跌或反映部分投资者选择获利了结。根据协议，荣昌生物将获得6.5亿美元首付款，并有资格获得最高49.5亿美元的里程碑付款及销售分成。该交易彰显了公司创新药物的全球竞争力，但短期股价波动属正常市场反应。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0},{"id":"2603644551","title":"泰它西普治疗眼肌型重症肌无力（OMG）Ⅲ期临床研究实现首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2603644551","media":"荣昌生物","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603644551?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:10","pubTimestamp":1768356653,"startTime":"0","endTime":"0","summary":"REMEGEN1月14日，荣昌生物宣布：注射用泰它西普治疗眼肌型重症肌无力的国内Ⅲ期临床研究，已完成首例患者入组给药。2025年5月，泰它西普治疗全身型重症肌无力已在国内获批上市。泰它西普这项治疗OMG的多中心、随机、双盲、安慰剂对照的Ⅲ期临床研究，计划纳入120例受试者。此前，泰它西普治疗重症肌无力适应症良好的疗效和安全性已获证实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114102109953cac45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114102109953cac45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","09995","BK1574","BK1161","LU2328871848.SGD"],"gpt_icon":0},{"id":"2603540866","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540866","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603540866?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:04","pubTimestamp":1768352684,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，荣昌生物 宣布与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，公司将收到6.5亿美元首付款、最高49.5亿美元的里程碑收款、以及两位数百分比的分级销售提成。随着关键产品相继BD出海，2026年该机构看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的推进，相关数据读出有望持续催化股价。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973172","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"2603652812","title":"荣昌生物频获跨国巨头追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652812","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603652812?lang=zh_cn&edition=full","pubTime":"2026-01-14 07:00","pubTimestamp":1768345200,"startTime":"0","endTime":"0","summary":"同时，与全球TOP级肿瘤药企艾伯维合作，有助于提升荣昌生物在国际市场的品牌与议价能力。此外，海外市场开发的高投入与监管风险由艾伯维承担，使荣昌生物可以更专注于中国市场及后续管线布局。事实上，艾伯维与荣昌生物的合作并非孤例，2025年以来，PD-1/VEGF双抗领域的BD交易已成为行业常态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114073445a4c08442&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114073445a4c08442&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","LU1969619763.USD","BK1583","09995","LU2328871848.SGD"],"gpt_icon":0},{"id":"2603168844","title":"智通港股通活跃成交|1月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603168844?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:00","pubTimestamp":1768302001,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月13日当天，阿里巴巴-W、腾讯控股、小米集团-W位居沪港通（南向）成交额前3位，成交额分别为81.05 亿元、29.45 亿元、28.57 亿元；阿里巴巴-W、腾讯控股、小米集团-W 位居深港通（南向）成交额前3位，成交额分别为58.01 亿元、23.48 亿元、21.05 亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999001051.SGD","LU0661504455.SGD","LU0541502299.USD","LU0737861772.HKD","BK1575","IE00BZ08YT58.USD","LU1642822792.SGD","LU0307460666.USD","BK1576","BK4538","IE00B3M56506.USD","SGXZ99366536.SGD","BK4220","GB00BDT5M118.USD","LU1814569148.SGD","LU2362540622.SGD","LU1880398471.USD","LU1282651121.HKD","LU2237443978.SGD","BK1193","LU0488056044.USD","LU1196710864.SGD","LU1048484197.HKD","SG9999002463.SGD","LU0449515922.USD","LU0456846285.SGD","LU1868838027.USD","LU1629966141.USD","LU0871576103.HKD","LU0531970944.HKD","BK1526","LU0211977185.USD","LU0648948544.HKD","LU1242518857.USD","LU1568876251.USD","IE0008369823.USD","IE00B031J352.USD","IE00BQXX3C00.GBP","LU0143863784.USD","LU0823041008.USD","LU1023057109.AUD","LU1961090484.USD","LU0127658192.USD","LU1003077747.HKD","LU0572940350.SGD","LU0611395673.USD","BK1590","LU1048596156.SGD","LU0251143458.SGD","LU0588545490.SGD","SG9999007991.SGD","LU1051768304.USD","89988","LU0329678337.USD","LU1993786604.SGD","BK1501","LU1733274390.USD","LU2399975544.HKD","BK1095","LU0882747503.HKD","HK0000914686.HKD","LU1688375341.USD","LU1808992512.USD","SG9999002828.SGD","IE0031814852.USD","LU0762541174.USD","BK1608","LU0084288322.USD","LU0314109678.HKD","LU0441854154.USD","688331","LU0543330483.HKD","LU2008162690.USD","IE0003895053.USD","LU1196710195.USD","LU0572939691.SGD","HXXD.SI","LU0359201612.USD","LU0797268264.HKD","SG9999015945.SGD","LU0164872284.USD","LU1720051108.HKD","LU0545039389.USD","LU1226287875.USD","LU1051769294.HKD","LU1316542783.SGD","LU2097828474.EUR","BK4526","LU0348783662.USD","LU0577902298.EUR","SG9999001689.USD","BABA","LU0648000940.SGD","HK0000320223.HKD","LU0865486749.SGD","IE0008368411.USD","LU0633140560.USD","LU0210526637.USD","LU1044874839.SGD","LU0828237940.HKD","09926","LU0320764243.SGD","IE00B97KM107.HKD","LU0345769631.USD","BK1516","LU0700851271.USD","IE00B0169L03.USD","BK4614","LU0823039010.USD","LU0320764755.SGD","LU0054237671.USD","LU0561508036.HKD","LU0605514214.HKD","LU1328615791.USD","LU0011963245.USD","LU1048588211.SGD","LU0163747925.USD","IE0008368304.USD","LU0048580855.USD","IE00B031HY20.USD","LU0261950983.USD","LU0231483743.USD","LU0047713382.USD","LU0315179316.USD","LU0791590937.USD","LU0630378692.HKD","LU1044875133.USD","SG9999015952.SGD","SG9999014914.USD","LU1105468828.SGD","81024","02208","02228","LU1769817179.HKD","LU0588545730.USD","02269","LU0819123356.HKD","BK1589","IE00B031HW06.USD","LU1046421795.USD","LU2097828631.EUR","LU1969619763.USD","LU0675040207.SGD","LU0117844026.USD","LU0762540952.USD","LU0633140727.USD","LU0235996351.USD","LU2293587155.HKD","BK4565","LU0359202008.SGD","LU0061477393.USD","LU0516422952.EUR","HK0000320264.USD","LU0873338254.USD","BK4527","LU0096374516.USD","LU1794554557.SGD","LU1675838814.USD","SGXZ51526630.SGD","LU0106959298.USD","LU2449936058.SGD","LU0197773160.USD","LU0738911758.USD","LU1008478684.HKD","LU0577902454.USD","LU1282649141.HKD","SG9999013353.USD","LU0608807946.USD","IE00BZ08YS42.EUR","LU2265009873.SGD","IE00BZ08YR35.GBP","LU0823413660.USD","LU0608807433.USD","LU0577902538.SGD","LU0048388663.USD","LU1481107354.HKD","LU0456842615.SGD","LU0143863198.USD","LU0315178854.USD","80883","LU0463099449.HKD","IE00B5MMRT66.SGD","LU0414403682.SGD","LU0348788117.USD","LU1282651048.USD","LU1115378108.SGD","LU0106259558.USD","LU1880383440.USD","LU1568876335.HKD","LU0878004406.USD","LU0651947912.USD","LU0828237510.HKD","600938","00700","LU0259732245.USD","BK4531","LU1981816686.USD","LU1196710351.USD","LU1956131251.USD","LU2328871848.SGD","LU0348825331.USD","LU0348767384.USD","LU0051755006.USD","LU0918141887.USD","LU2023250504.SGD","LU0196878994.USD","LU0128525689.USD","SGXZ31699556.SGD","LU0502904849.HKD","HK0000352291.HKD","BK1523","SG9999001226.SGD","BK1142","LU1720050803.USD","LU1226288170.HKD","LU0132412106.USD","SG9999018865.SGD","SG9999014906.USD","LU0326948709.USD","BK4607","LU0359201885.HKD","LU1770034418.SGD","LU2097829019.USD","LU0594300419.USD","LU2045819591.USD","BK0214","BK1546","BK4575","LU0130518102.USD","LU0708995153.HKD","SG9999000459.SGD","BK1205","BK1517","LU0164865239.USD","LU1548497426.USD","LU1951186391.HKD","BK4503","HK0000165453.HKD","LU1497733631.SGD","BK1513","BK4533","LU0149534421.HKD","LU0828238088.HKD","BK4534","LU0821914370.USD","BK1536","BK1615","LU1152091168.USD","BK1531","BK4558","LU2133065610.SGD","LU0052756011.USD","LU0737861699.HKD","KSTmain","LU0456827905.SGD","LU0516422366.SGD","LU0396098781.USD","BK1614","IE00B0169N27.USD","LU0348735423.USD","LU1282649067.USD","LU0210533765.USD","LU1439103000.SGD","BK4524","LU0326950275.SGD","LU0650527681.SGD","BK1152","LU2097828557.USD","LU0501845795.SGD","LU2498475776.HKD","00981","LU0630378429.USD","IE0009570106.USD","IE00BQXX3D17.EUR","LU0264606111.USD","LU0499858602.USD","LU0348784397.USD","LU0553294199.USD","LU0509642566.USD","LU0210527791.USD","BK1618","LU1439102457.SGD","BK1528","BK4505","LU0049112450.USD","BK4579","LU0577902611.USD","81810","LU1655091459.SGD","LU1235295612.USD","BK4548","LU0229945570.USD","BK4587","BK1233","LU0449509016.USD","LU2097828714.EUR","LU0543330566.HKD","IE00B067MR52.USD","LU0203345920.USD","LU0634319403.HKD","LU1235294995.USD","LU0106252389.USD","LU0287142896.SGD","LU0214875030.USD","BK4543","IE0034224299.USD","LU0516422440.USD","LU0949170772.SGD","LU2148510915.USD","IE0032431581.USD","LU0130103400.USD","LU0791591158.USD","BK4554","LU2226246903.HKD","SGXZ90724238.SGD","LU0831093199.SGD","LU0175139822.USD","LU0823040885.USD","LU0173614495.USD","09988","LU0738912210.USD","LU0348723411.USD","LU2476274308.USD","LU0169518387.USD","LU0328353924.USD","METmain","IE00BQXX3F31.USD","LU1224709979.USD","LU1226287529.USD","BK1161","LU1810669033.SGD","HK0000306701.USD","BK4502","LU0455707207.USD","SG9999014880.SGD","LU0289960550.SGD","LU0823413587.USD","LU2237443465.HKD","BK1249","LU0640798160.USD","BK1583","LU0029874905.USD","LU0348805143.USD","LU2362541513.USD","LU0417516902.SGD","LU1188198961.HKD","LU0516423174.USD","LU1634259557.SGD","LU0831103253.SGD","LU1224444064.USD","03690","LU0823426308.USD","LU3063872942.SGD","LU2251237488.HKD","LU1282649810.SGD","LU0898667661.SGD","BK1238","SGXZ81514606.USD","LU1504937902.USD","SG9999001093.SGD","IE00B29SXG58.USD","LU1226288097.SGD","BK4535","LU0269904917.USD","LU1868837565.USD","LU0072462343.USD","LU2051468812.USD","SG9999018857.SGD","LU0310800965.SGD","LU1515016050.SGD","LU0348766576.USD","688981","SG9999015986.USD","SGXZ49509284.SGD","LU0384037296.USD","01024","LU0067412154.USD","LU0348827113.USD","LU0862451837.USD","LU2237443549.SGD","LU1880398554.USD","LU0128522157.USD","LU0651946864.USD","LU2247934214.USD","HMTD.SI","LU0345776255.USD","LU1868837722.USD","LU2237443622.USD","002202","SG9999002562.SGD","LU1733274473.HKD","LU1718418525.SGD","LU0140636845.USD","LU0572944931.SGD","LU2125910500.SGD","SG9999000327.SGD","LU1152091754.HKD","LU0972618739.USD","HK0000306685.HKD","HBBD.SI","LU0228659784.USD","LU2148611432.USD","IE00BF5LJ272.USD","LU0886674414.USD","LU2279701549.SGD","BK1521","LU1720051017.SGD","LU2362541273.HKD","BK1502","IE00B0JY6N72.USD","LU0149721374.USD","LU0431992006.USD","LU0345775950.USD","LU1201861165.SGD","LU2242644610.SGD","LU1813983027.USD","LU0181495838.USD","IE0003851619.USD","LU1102505929.USD","LU1770036033.HKD","SG9999017495.SGD","LU1211504680.USD","LU1242518931.SGD","LU0107464264.USD","LU1807302812.USD","LU1323998911.USD","LU2177674079.SGD","LU0211331839.USD","LU2257852520.SGD","LU0819121731.USD","LU0188438112.USD","LU0197773673.USD","LU2125910849.SGD","SG9999000418.SGD","LU0054450605.USD","LU1064130708.USD","IE00BFMHRM44.USD","IE00BMPRXR70.SGD","BK4585","BK4581","IE0032834883.USD","LU1823568750.SGD","BK4588","BK1607","LU0577902371.SGD","SG9999003461.SGD","BK4504","HTCD.SI","LU0708995583.HKD","LU0762542818.HKD","BK1584","LU1303224171.USD","LU0593848301.USD","BK1609","LU0477156797.USD","LU0890818403.SGD","600941","00941","LU1719994722.HKD","LU2237443895.HKD","LU1880383366.USD","LU2251237306.USD","SG9999004220.SGD","BK1574","SG9999014674.SGD","LU1734074674.USD","LU2462611646.USD","LU0072913022.USD","LU2476274720.SGD","LU0228367735.SGD","HK0000252160.HKD","BK1604","LU2152927971.USD","LU0823397103.USD","LU0293314216.USD","SG9999015978.USD","IE0003795394.USD","LU0784639295.USD","LU1282648689.USD","BK1163","LU0541501648.USD","HK0000500386.USD","LU2317271919.USD","BK1141","LU0469268626.HKD","LU0417516571.SGD","LU1634259391.SGD","LU0540923850.HKD","BK1610","LU0918141705.HKD","LU0823426480.USD","LU1974910355.USD","LU0531971595.HKD","LU0203347892.USD","LU1064131003.USD","LU2357305700.SGD","IE0001KFT4U8.USD","LU0862451753.SGD","LU0588545904.SGD","LU2097828805.USD","LU0039217434.USD","LU0070217475.USD","LU0348783233.USD","LU0048597586.USD","01810","LU0254981946.USD","BK1586","SG9999001069.SGD","LU1831875114.USD","LU2087589342.USD","LU0320764599.SGD","LU1804176565.USD","IE00BMPRXN33.USD","LU0049853897.USD","LU0979878070.USD","LU0823397285.USD","LU0052750758.USD","LU0856984785.SGD","LU0878005551.USD","LU1917777945.USD","IE00B8L5B284.USD","LU0345769128.USD","BK1591","LU0029875118.USD","LU0192582467.USD","LU0043850808.USD","IE00B543WZ88.USD","LU0251144936.SGD","LU1226288253.USD","IE0008368742.USD","HK0000914660.USD","LU1328277881.USD","SGXZ81163826.USD","LU1769817096.USD","LU1497734951.SGD","SG9999001903.USD","LU1725190679.HKD","LU2106854487.HKD","LU1251922891.USD","LU0594300179.USD","LU0607220059.USD","LU1226287792.SGD","LU1497733557.USD","LU0417516738.SGD","IE00BGV7N243.SGD","BK1558","LU0329678170.USD","LU0499858438.USD","LU0672654166.SGD","LU1960683339.HKD","BK1617","LU0823038988.USD","09995","LU1044876610.USD","LU0128522744.USD","LU1883866441.USD","BK4122","IE00BPRC5H50.USD","LU1366334651.USD","00883","LU0348814723.USD","LU2778985437.USD","IE00B8HQ1Z84.USD","LU1522347837.USD","LU0261947096.USD","BK1506","LU0516423091.SGD","SG9999006597.SGD","LU2237443382.USD","LU0164880469.USD","LU0588546209.SGD","LU0786609619.USD","SG9999006514.SGD","LU0683595622.HKD","LU1366334578.USD","SG9999014898.SGD","LU1046422090.SGD","BK1594","HK0000252152.HKD","LU1102505762.USD","HK0000352382.USD","LU0165289439.USD","LU0348816934.USD","LU2039709279.SGD","LU0642271901.SGD","LU0117841782.USD","LU0880133367.SGD","LU2488822045.USD","LU0589944569.HKD","LU0985320562.USD","LU0080751232.USD","BK1588","SG9999001846.SGD","LU0244354667.USD","LU0868486357.SGD","LU1267930227.SGD","LU1785774172.SGD","LU0327786744.USD","LU0370786039.SGD"],"gpt_icon":0},{"id":"2603023639","title":"每日卖空追踪 | 荣昌生物 01月13日卖空量成交184.95万股，卖空比例为9.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603023639","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603023639?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:30","pubTimestamp":1768293042,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间01月13日，涨7.87%，卖空量成交184.95万股，较上一交易日增加846.04%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113165651a7150a98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113165651a7150a98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09995","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2603639049","title":"荣昌生物01月13日获主力加仓8504.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603639049","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603639049?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:15","pubTimestamp":1768292148,"startTime":"0","endTime":"0","summary":"01月13日, 荣昌生物股价涨7.87%，报收100.10元，成交金额19.9亿元，换手率9.34%，振幅7.60%，量比4.15。荣昌生物今日主力资金净流入8504.0万元，连续7日净流入，上一交易日主力净流入1085.6万元。该股近5个交易日上涨22.48%，主力资金累计净流入1.8亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.1亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113162417a714e80b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113162417a714e80b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","09995"],"gpt_icon":0},{"id":"2603239505","title":"港股“子”曰 | 56亿美元利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2603239505","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603239505?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:41","pubTimestamp":1768290101,"startTime":"0","endTime":"0","summary":"港股创新药，可能又要热闹起来了。今天，消息面最大的利好，来自荣昌生物（HK09995）。荣昌生物昨晚公布了重量级利好：艾伯维（纽约证券交易所代码：ABBV）和荣昌生物宣布签署独家授权许可协议，共同开发、生产以及商业化RC148。根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617327193.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617327193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","09995","06978","BK1574","BK1583","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"1135640998","title":"BD大单扎堆、龙头业绩预增翻倍，港A创新药掀起暴涨浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=1135640998","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135640998?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:25","pubTimestamp":1768289121,"startTime":"0","endTime":"0","summary":"BD合作密集披露近期，被誉为“医药春晚”的行业盛会顺利召开，进一步点燃了医药板块的市场热度。1月12日，药明康德发布2025年度业绩预告，多项核心指标实现强劲增长。1月7日，恒瑞医药公告称，1类创新药瑞拉芙普α注射液获批上市国内外尚无同类产品获批上市。华泰证券表示，自10月以来，BD出海交易共计发生49单，总金额超过390亿美元。有部分市场预期较高的BD虽然有时间上的推迟，但交易持续进展，创新药出海趋势一如既往。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d9a285c5d35960016c392e2c485f56f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3569925","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02359","02269","09995"],"gpt_icon":0},{"id":"2603577631","title":"国产双抗再爆发：荣昌生物达成首付款6.5亿美元BD，盘中一度涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2603577631","media":"澎湃新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603577631?lang=zh_cn&edition=full","pubTime":"2026-01-13 13:25","pubTimestamp":1768281912,"startTime":"0","endTime":"0","summary":"1月13日，荣昌生物（688331.SH；9995.HK）A股高开，截至午盘，A股20cm涨停，港股涨超11%。消息面上，1月12日晚间，荣昌生物公告称，与知名跨国药企艾伯维（AbbVie）就荣昌生物自主研发的新型靶向PD-1/VEGF的双特异性抗体药物RC148签署独家授权许可协议。根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617176389.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617176389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","688331","BK1583","09995","LU2488822045.USD","LU1064130708.USD","BK1161","BK0239","BK1574","LU2328871848.SGD"],"gpt_icon":0},{"id":"2603950262","title":"A股、港股医药股今日大涨，这些利好因素在刺激","url":"https://stock-news.laohu8.com/highlight/detail?id=2603950262","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603950262?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:37","pubTimestamp":1768275475,"startTime":"0","endTime":"0","summary":"1月13日上午，A股以及港股的医药股集体出现走强趋势。当前，已有重磅对外授权交易揭晓。这笔交易刺激了A股、港股市场中的一些双抗概念股股价大涨，1月13日上午，宜明昂科港股股价盘中涨幅一度超过10.10%；三生国健A股股价涨幅也超过4%。同样，A股以及港股的医药外包股齐齐出现股价大涨局面，如药明康德A股跟港股上午盘中股价涨幅超过6%；药明生物股价涨幅也超过5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113113932a4bcec89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113113932a4bcec89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B0JY6N72.USD","LU0417516738.SGD","LU0516422952.EUR","LU0327786744.USD","LU0039217434.USD","02126","LU0051755006.USD","LU0348825331.USD","LU0320764599.SGD","LU1794554557.SGD","LU0516423174.USD","LU0043850808.USD","LU0979878070.USD","BK1515","02179","BK1574","LU0516423091.SGD","LU0823426480.USD","01541","BK1161","LU0181495838.USD","09939","LU0516422366.SGD","LU0516422440.USD","LU0417516902.SGD","LU0708995583.HKD","LU2328871848.SGD","LU0856984785.SGD","LU1880383366.USD","LU2039709279.SGD","LU3063872942.SGD","02269","LU0359201612.USD","LU0588546209.SGD","LU1242518931.SGD","BK1576","LU1969619763.USD","LU0823426308.USD","LU0359202008.SGD","LU1242518857.USD","LU0307460666.USD","LU0456827905.SGD","LU0052750758.USD","02616","09995","BK1610","LU1688375341.USD","LU1720050803.USD","SG9999002562.SGD","LU0819121731.USD"],"gpt_icon":0},{"id":"2603275579","title":"异动快报：荣昌生物（688331）1月13日11点25分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603275579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603275579?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:30","pubTimestamp":1768275040,"startTime":"0","endTime":"0","summary":"证券之星1月13日盘中消息，11点25分荣昌生物触及涨停板。其所属行业生物制品目前上涨。领涨股为近岸蛋白。该股为创新药，健康中国，医药概念热股，当日创新药概念上涨2.7%，健康中国概念上涨2.51%，医药概念上涨2.3%。1月12日的资金流向数据方面，主力资金净流出826.53万元，占总成交额1.25%，游资资金净流入2303.75万元，占总成交额3.49%，散户资金净流出1477.22万元，占总成交额2.24%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300015725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","LU1969619763.USD","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","LU2328871848.SGD","BK1574","LU2488822045.USD","688331","09995","BK0239","BK1161"],"gpt_icon":0},{"id":"2603575987","title":"商业航天大面积跌停，AI应用继续大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575987","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575987?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:06","pubTimestamp":1768270010,"startTime":"0","endTime":"0","summary":"大河财立方记者 夏晨翔 任浩鹏1月13日开盘，A股三大指数集体高开后震荡，医疗、CRO、生物科技、AI应用、文化传媒、虚拟人、AIGC、保险等概念涨幅居前；商业航天、卫星导航、低空经济、卫星互联网等概念跌幅居前。12日晚间，多个热门赛道概念股发布异常波动、风险提示、停牌核查公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1610","LU0634319403.HKD","LU1023057109.AUD","LU2097828805.USD","LU2449936058.SGD","SG9999006597.SGD","300063","BK1540","LU0143863784.USD","LU0259732245.USD","LU0708995583.HKD","LU0509642566.USD","LU0348825331.USD","LU0823039010.USD","LU0871576103.HKD","LU0359202008.SGD","LU0561508036.HKD","LU0164872284.USD","LU0516423091.SGD","SG9999015952.SGD","BK1522","LU0084288322.USD","LU0254981946.USD","LU0359201612.USD","03986","BK1539","LU1808992512.USD","LU0315178854.USD","LU2476274720.SGD","LU1720050803.USD","603598","LU2506951792.HKD","LU0650527681.SGD","LU1880383440.USD","LU2097828474.EUR","LU0348827113.USD","LU0214875030.USD","LU0543330566.HKD","LU0979878070.USD","LU0856984785.SGD","LU2294711713.HKD","LU2153592121.USD","LU0054450605.USD","LU0823414551.USD","LU1242518857.USD","002594","LU0417516902.SGD","LU0314109678.HKD","LU0175139822.USD","LU0588546209.SGD","LU0823038988.USD","81211","LU0327786744.USD","LU0449515922.USD","LU0320764599.SGD","LU0588545904.SGD","LU0605514214.HKD","LU2476274308.USD","LU1868837722.USD","300785","LU0594300419.USD","LU2039709279.SGD","600880","LU0269904917.USD","SG9999014674.SGD","02359","600151","LU1251922891.USD","00241","LU1303224171.USD","LU1961090484.USD","LU2097828631.EUR","LU0531971595.HKD","HYDD.SI","301230","LU1861214812.USD","002149","LU0289961442.SGD","LU0307460666.USD","LU0348805143.USD","LU0229945570.USD","LU0039217434.USD","LU0516422440.USD","LU0417516738.SGD","LU1242518931.SGD","601698","LU2357125470.USD","BK1509","LU0823426480.USD","LU0289960550.SGD","688331","BYDDY","LU0165289439.USD","LU1868838027.USD","LU0819121731.USD","LU1770034418.SGD","LU2249611893.SGD","LU0540923850.HKD","BK1594","SG9999015945.SGD","SG9999002463.SGD","LU0516422952.EUR","300244","600986","LU0594300179.USD","LU1794554557.SGD","LU0289739343.SGD","LU0505663152.USD","LU0516422366.SGD","603259","LU0359201885.HKD","LU0164865239.USD","LU0823414478.USD","01211","000547","SG9999006514.SGD","LU0572944931.SGD","LU2360107325.USD","LU2399975544.HKD","LU0593848301.USD","09868","LU1868837565.USD","LU1861219969.SGD","BK1119","LU0819123356.HKD","LU0588545490.SGD","09995","LU0348735423.USD","IE00BD6J9T35.USD","LU0531970944.HKD","LU0043850808.USD","LU0211977185.USD","301171","09988","SG9999001226.SGD","LU0865486749.SGD","SG9999015978.USD","BK1582","LU0052750758.USD","LU0463099449.HKD","LU0588545730.USD","LU0516423174.USD","002413","LU0511384066.AUD","LU0449509016.USD","LU0469268626.HKD","LU0326950275.SGD","LU0828238088.HKD","603986","LU2348774022.SGD","SG9999015986.USD","SG9999002828.SGD","LU0244354667.USD","LU0823426308.USD","LU1719994722.HKD","LU1328277881.USD","LU2097828714.EUR","LU1188198961.HKD","LU2778985437.USD","LU1813983027.USD","002131","LU2097828557.USD","LU1880383366.USD","002044","LU0143863198.USD"],"gpt_icon":1},{"id":"2603357301","title":"PD-1/VEGF双抗交易热潮回归？荣昌生物签下56亿美元授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603357301","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603357301?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:03","pubTimestamp":1768269780,"startTime":"0","endTime":"0","summary":"艾伯维拿下荣昌生物的双抗授权。　　1月12日晚间，中国生物医药企业荣昌生物宣布，与艾伯维达成一笔总金额高达56亿美元的授权合作。　　RC148是荣昌生物研发的一款新型靶向PD-1/VEGF的双特异性抗体药物，其设计旨在激活抗肿瘤免疫反应的同时抑制肿瘤驱动的血管生成。通过同时靶向并抑制PD-1与VEGF通路，有望通过多机制增强免疫系统的抗肿瘤活性。　　值得一提的是，康方生物PD-1/VEGF再度传来新的进展消息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2148510915.USD","LU1169590202.USD","BK1583","LU1064131003.USD","BK1161","LU2328871848.SGD","09995","BK1574","LU1064130708.USD","LU1169589451.USD","PD","688331","BK4023","LU2488822045.USD","BK0239","LU1969619763.USD"],"gpt_icon":0},{"id":"1161784801","title":"异动解读 | 荣昌生物盘中大涨8.84%，与艾伯维达成56亿美元重磅授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1161784801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161784801?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:30","pubTimestamp":1768267834,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中大涨8.84%，引发市场广泛关注。消息面上，荣昌生物于1月12日宣布与跨国药企艾伯维签署独家授权许可协议，将其自主研发的PD-1/VEGF双特异性抗体药物RC148在大中华区以外的开发、生产和商业化权利授予艾伯维。根据协议，荣昌生物将获得6.5亿美元的首付款，并有资格获得最高达49.5亿美元的里程碑付款及销售分成，总交易金额最高可达56亿美元。此次与艾伯维的合作不仅为荣昌生物带来急需的资金支持，也彰显了其创新药物的全球竞争力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.2428},{"period":"3month","weight":-0.0256},{"period":"6month","weight":0.3166},{"period":"1year","weight":6.5242},{"period":"ytd","weight":0.2938}],"compareEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.0535},{"period":"3month","weight":0.0429},{"period":"6month","weight":0.0876},{"period":"1year","weight":0.4048},{"period":"ytd","weight":0.0534}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.089454},{"month":2,"riseRate":0.8,"avgChangeRate":0.209338},{"month":3,"riseRate":0.4,"avgChangeRate":-0.022811},{"month":4,"riseRate":0.8,"avgChangeRate":0.104301},{"month":5,"riseRate":0.4,"avgChangeRate":-0.023394},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}